1,898 reports of this reaction
8.9% of all AXICABTAGENE CILOLEUCEL reports
#2 most reported adverse reaction
IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY SYNDROME is the #2 most commonly reported adverse reaction for AXICABTAGENE CILOLEUCEL, manufactured by Kite Pharma, Inc.. There are 1,898 FDA adverse event reports linking AXICABTAGENE CILOLEUCEL to IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY SYNDROME. This represents approximately 8.9% of all 21,373 adverse event reports for this drug.
Patients taking AXICABTAGENE CILOLEUCEL who experience immune effector cell associated neurotoxicity syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY SYNDROME is moderately reported among AXICABTAGENE CILOLEUCEL users, representing a notable but not dominant share of adverse events.
In addition to immune effector cell associated neurotoxicity syndrome, the following adverse reactions have been reported for AXICABTAGENE CILOLEUCEL:
IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY SYNDROME has been reported as an adverse event in 1,898 FDA reports for AXICABTAGENE CILOLEUCEL. This does not prove causation, but indicates an association observed in post-market surveillance data.
IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY SYNDROME accounts for approximately 8.9% of all adverse event reports for AXICABTAGENE CILOLEUCEL, making it one of the most commonly reported side effect.
If you experience immune effector cell associated neurotoxicity syndrome while taking AXICABTAGENE CILOLEUCEL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.